The cost-cutting plan Pear Therapeutics announced in July has not done enough to change the company’s financial outlook, suggesting the company’s strategy to sell digital therapeutics to state health agencies is not nearly as effective as the company’s investors had hoped.
The restructuring plan that Pear announced last summer included two rounds of layoffs, cutting about 20% of the company’s staff....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?